Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

ABSTRACT:

SUBMITTER: Ou SH 

PROVIDER: S-EPMC4319629 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature